Novo Nordisk's China President Zhou to step down in March
Danish pharmaceutical company Novo Nordisk said on Friday that Senior Vice President and head of its business in China Christine Zhou will leave the company at the end of March.
Novo Nordisk: Investors May Be In For An Earnings Surprise
Novo Nordisk could be poised for a temporary negative sentiment swing as Q4 earnings may include highly conservative 2026 guidance despite strong oral Wegovy prescription momentum. Recent news - such as oral Wegovy's rapid uptake, Lilly's FDA delays, UK approval, and an Amazon partnership have all fueled a 20% rally, but upside appears limited pre-earnings. Management is likely to under promise on 2026 guidance to set up a runway for consistent beats and positive revisions as oral Wegovy's impact materializes, in my view.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO) reached $62.89 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill launched in January 2026 with 18,000+ prescriptions in its debut week, expanding the addressable market to approximately 85 million Americans. Catalent fill-finish site integration is expected to double U.S. supply chain capacity by mid-2026, supporting margin expansion and reducing manufacturing bottlenecks going forward.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog
Novo Nordisk was excessively punished by the market, trading at a significant discount to Eli Lilly despite robust fundamentals and global leadership in metabolic disease. NVO's global infrastructure, especially outside the U.S., and its oral GLP-1 program position it for long-term relevance as obesity pharmacotherapy expands worldwide. Recent valuation divergence was more amplified by retail-driven narrative momentum than by fundamental business deterioration; the stock's drop below $50 represented an overreaction.
Novo Nordisk: This Run Is Just Getting Started
Novo Nordisk A/S stock has jumped 30% since my last coverage. NVO's first-mover advantage in oral GLP-1 positions it well despite rising competition and pricing pressures in obesity and diabetes markets. The company's long-term prospects are bright, and NVO stock appears undervalued.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
Novo Nordisk (NVO) closed the most recent trading day at $59.32, moving 2.24% from the previous trading session.
Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026
Novo Nordisk A/S is poised for a turnaround in 2026, driven by renewed strategic focus under new CEO Maziar Doustdar. NVO's core strengths in diabetes and obesity, particularly with semaglutide, underpin expectations for double-digit revenue and EPS growth. The launch of oral Wegovy, with superior efficacy and tolerability, positions NVO competitively against Eli Lilly's delayed oral GLP-1 entrant.
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
